| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2013 | US20130137756 Modulation of human mouse double minute 2 homolog activity |
| 05/30/2013 | US20130137749 Compositions and Methods for Gene Silencing |
| 05/30/2013 | US20130137747 Double-stranded rna-based nanoparticles for insect gene silencing |
| 05/30/2013 | US20130137744 Pyrrolidine triple reuptake inhibitors |
| 05/30/2013 | US20130137743 Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| 05/30/2013 | US20130137742 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 05/30/2013 | US20130137741 Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
| 05/30/2013 | US20130137740 Combretastatin analogs for use in the treatment of cancer |
| 05/30/2013 | US20130137736 Methods for Treating Degenerative Diseases/Injuries |
| 05/30/2013 | US20130137735 Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naph-thalenecarboxamide |
| 05/30/2013 | US20130137733 Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses |
| 05/30/2013 | US20130137730 Inhibitor of casein kinase 1delta and casein kinase 1e |
| 05/30/2013 | US20130137729 Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| 05/30/2013 | US20130137727 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 05/30/2013 | US20130137725 Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| 05/30/2013 | US20130137724 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for retinal neuroprotection |
| 05/30/2013 | US20130137723 Crystal of anti-bacterial compound |
| 05/30/2013 | US20130137722 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| 05/30/2013 | US20130137717 Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof |
| 05/30/2013 | US20130137716 Parenteral dextrose formulation of clopidogrel |
| 05/30/2013 | US20130137714 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders |
| 05/30/2013 | US20130137713 Methods for treating bowel diseases |
| 05/30/2013 | US20130137711 Polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
| 05/30/2013 | US20130137710 Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
| 05/30/2013 | US20130137709 Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| 05/30/2013 | US20130137707 Pyrazolopyrimidine pde 10 inhibitors |
| 05/30/2013 | US20130137702 Anticoagulant reversal agents |
| 05/30/2013 | US20130137701 Combination |
| 05/30/2013 | US20130137699 Therapeutic compounds |
| 05/30/2013 | US20130137697 Compositions, methods of use, and methods of treatment |
| 05/30/2013 | US20130137696 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases |
| 05/30/2013 | US20130137695 Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase-1 inhibitors |
| 05/30/2013 | US20130137690 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| 05/30/2013 | US20130137689 Novel acylpiperazinones and their use as pharmaceuticals |
| 05/30/2013 | US20130137686 Benzene, pyridine, and pyridazine derivatives |
| 05/30/2013 | US20130137684 Haematopoietic-prostaglandin d2 synthase inhibitors |
| 05/30/2013 | US20130137681 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| 05/30/2013 | US20130137679 Novel Functionally Selective Ligands of Dopamine D2 Receptors |
| 05/30/2013 | US20130137677 Bicyclic Azaheterocyclic Carboxamides |
| 05/30/2013 | US20130137669 Macrocyclic lactone resistance marker for dirofilaria immitis |
| 05/30/2013 | US20130137668 Antimicrobial Cationic Steroids and Methods of Use |
| 05/30/2013 | US20130137667 Ligands for nematode nuclear receptors and uses thereof |
| 05/30/2013 | US20130137666 Combinations of niacin compounds, omega-3 fatty acid compounds, and phytosterol compounds for prevention and/or mitigation of erectile dysfunction |
| 05/30/2013 | US20130137665 Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| 05/30/2013 | US20130137664 Low-dosed solid oral dosage forms for hrt |
| 05/30/2013 | US20130137663 Methods and compositions for reducing parathyroid levels |
| 05/30/2013 | US20130137662 Use of canthaxanthin and/or 25-oh d3 for improved reproductivity and performance of roosters |
| 05/30/2013 | US20130137659 Anticancer derivatives, preparation thereof and therapeutic use thereof |
| 05/30/2013 | US20130137657 Quaternised ammonium cyclodextrin compounds |
| 05/30/2013 | US20130137655 Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same |
| 05/30/2013 | US20130137652 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent |
| 05/30/2013 | US20130137650 Methods of treatment using combination therapy |
| 05/30/2013 | US20130137649 Epigenetic mechanisms of anti-fibrotic action for the liver |
| 05/30/2013 | US20130137648 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 05/30/2013 | US20130137647 Natural medicinal compound |
| 05/30/2013 | US20130137646 Methods of treatment, pharmaceutical compositions and uses thereof |
| 05/30/2013 | US20130137643 Maternal sialic acid supplementation |
| 05/30/2013 | US20130137642 Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| 05/30/2013 | US20130137640 Skin Collagen Enhancing Agent |
| 05/30/2013 | US20130137635 Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
| 05/30/2013 | US20130137634 Compounds and compositions for ossification and methods related thereto |
| 05/30/2013 | US20130137629 Combination treatment for metabolic disorders |
| 05/30/2013 | US20130137191 Method and kit for detecting the early onset of renal tubular cell injury |
| 05/30/2013 | US20130137177 Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof |
| 05/30/2013 | US20130137116 Method and kit for detecting the early onset of renal tubular cell injury |
| 05/30/2013 | US20130136813 Anti-inflammatory compositions |
| 05/30/2013 | US20130136811 Compositions and Methods for Pain Reduction |
| 05/30/2013 | US20130136809 7-hyrdroxyfrullanolide its analogs for prevention control and treatment of metabolic disorders |
| 05/30/2013 | US20130136804 Crystal Forms of Kinase Inhibitors |
| 05/30/2013 | US20130136802 Treating male infertility secondary to sperm oxidative stress |
| 05/30/2013 | US20130136798 Novel parenteral controlled release formulations of nsaid's |
| 05/30/2013 | US20130136790 Liposomes with improved drug retention for treatment of cancer |
| 05/30/2013 | US20130136789 Agent for treating renal fibrosis |
| 05/30/2013 | US20130136788 Method for treating pulmonary disorders with liposomal amikacin formulations |
| 05/30/2013 | US20130136787 Liposomal Camptothecins and Uses Thereof |
| 05/30/2013 | US20130136782 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives |
| 05/30/2013 | US20130136778 Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injuries |
| 05/30/2013 | US20130136776 Compositions and methods for treating hepatitis c virus |
| 05/30/2013 | US20130136774 Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition |
| 05/30/2013 | US20130136772 Regulation of immune response by colocynthin and/or its derivatives |
| 05/30/2013 | US20130136771 Oligodeoxynucleotide and its use to induce an immune response |
| 05/30/2013 | US20130136770 Methods for treating respiratory viral infection |
| 05/30/2013 | US20130136769 Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| 05/30/2013 | US20130136762 Modified surface antigen |
| 05/30/2013 | US20130136757 Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof |
| 05/30/2013 | US20130136753 Paxillin as a therapeutic or diagnostic marker for cancer |
| 05/30/2013 | US20130136751 Methods, Compositions and Kits Relating to Chitnases and Chitnase-Like Molecules and Inflammation Disease |
| 05/30/2013 | US20130136743 Novel mutated humanized 12g4 antibodies and the fragments thereof against the human anti-mullerian hormone receptor type ii |
| 05/30/2013 | US20130136726 Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions |
| 05/30/2013 | US20130136724 Pig feed, and method for feeding same |
| 05/30/2013 | US20130136719 Compounds and methods for the treatment or prevention of flavivirus infections |
| 05/30/2013 | US20130136715 Wound healing compositions based on cyanoacrylates and 5,5-disubstitutedhydantoins, including phenytoin |
| 05/30/2013 | US20130136714 Functionalized polymer nanoparticles and the pharmaceutical use thereof |
| 05/30/2013 | US20130136704 P-menthane-3,8-diol isomer mixture, composition comprising the same, and products comprising the mixture or composition |
| 05/30/2013 | US20130136703 Limited release lingual thioctic acid delivery systems |
| 05/30/2013 | US20130136700 Poly-hapten with topical hormone alopecia hair regrowth system |
| 05/30/2013 | US20130136693 Crystal Forms of 2--Adenosine |
| 05/30/2013 | US20130136692 Molecular signature of cancer |
| 05/30/2013 | CA2856847A1 Oil compositions and methods for increasing hair growth and/or preventing hair loss |
| 05/30/2013 | CA2856803A1 Enhanced treatment regimens using mtor inhibitors |